United Therapeutics Corp. Stock Price, News & Analysis

United Therapeutics Corporation (Nasdaq: UTHR) announced it will report its third quarter 2020 financial results on October 28, 2020, before market opens. A teleconference will follow at 9:00 a.m. ET, accessible via phone and webcast on their website. The company emphasizes a commitment to innovation and quality, alongside efforts to address the shortage of transplantable organs through its subsidiary, Lung Biotechnology PBC. They caution that forward-looking statements may be subject to risks that could cause actual results to differ.

United Therapeutics Corporation (Nasdaq: UTHR) announced its presentation of clinical trial data on Tyvaso® (treprostinil) at CHEST 2020, scheduled from October 18-21. This will include results from the phase 3 INCREASE study focusing on pulmonary hypertension associated with interstitial lung disease (PH-ILD). Other topics include data on the Orenitram® ADAPT registry and the psychological impact of pulmonary arterial hypertension (PAH). Key presenters include Aaron Waxman and John Kingrey. The e-posters will be available on the CHEST 2020 website.

United Therapeutics Corporation (Nasdaq: UTHR) will have its CEO, Dr. Martine Rothblatt, present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23, 2020. The session will run from 11:40 a.m. to 12:20 p.m. EDT and will be accessible via a live webcast on the company's website. An archived version will be available 24 hours post-session for 90 days. United Therapeutics is dedicated to innovation in biotechnology, focusing on organ transplant technologies through its subsidiary, Lung Biotechnology PBC, which aims to address organ shortages.

United Therapeutics Corporation (Nasdaq: UTHR) appointed Dr. Linda Maxwell as an independent director on September 10, 2020. Dr. Maxwell, a distinguished head and neck surgeon and healthcare innovator, brings extensive expertise in medical education and health technology entrepreneurship. She has held significant positions in various academic institutions and has experience managing startups in clinical development. United Therapeutics emphasizes the value of her achievements in advancing human health and innovative approaches in biotechnology.

United Therapeutics Corporation (Nasdaq: UTHR) announced that the FDA accepted its supplemental New Drug Application for Tyvaso® (treprostinil) Inhalation Solution, targeting pulmonary hypertension associated with interstitial lung disease (PH-ILD). This potential approval would make Tyvaso the first treatment for about 30,000 affected patients in the U.S. The FDA review is expected to conclude in April 2021, based on positive results from the phase 3 INCREASE study, which demonstrated significant improvements in 6-minute walk distance and secondary endpoints.

United Therapeutics Corporation (Nasdaq: UTHR) announced an upcoming fireside chat on August 11, 2020, from 8:00 to 8:30 a.m. EDT, at the Wedbush PacGrow Healthcare Virtual Conference. Dr. Martine Rothblatt, the company's CEO, will provide an overview and update on their business strategy. The presentation can be accessed live on the United Therapeutics website, with an archived version available for 90 days post-event. The company focuses on innovative solutions for transplantable organs through its subsidiary, Lung Biotechnology PBC.

United Therapeutics Corporation (Nasdaq: UTHR) reported second-quarter 2020 results, revealing revenues of $362.0 million, down 3% from $373.6 million in 2019. Net income plummeted 48% to $107.1 million, with earnings per diluted share falling to $2.41. Despite challenges, including a 24% revenue drop for Remodulin due to generic competition and pandemic issues, Orenitram sales surged 40% following a label update. The company anticipates product launches in the near term, although certain projects face delays due to COVID-19-related disruptions.

United Therapeutics Corporation (Nasdaq: UTHR) announced a new patent for Tyvaso (treprostinil) Inhalation Solution, issued July 21, 2020, expiring May 14, 2027. This patent, U.S. Patent No. 10,716,793, includes claims for the dosing regimen of Tyvaso. The company has filed an amended complaint against Liquidia Technologies for patent infringement related to this new patent, amidst ongoing litigation over Liquidia's NDA for LIQ861. United Therapeutics aims to enforce its intellectual property rights, although the unpredictability of litigation presents risks.

United Therapeutics Corporation (Nasdaq: UTHR) plans to release its second quarter 2020 financial results on July 29, 2020, before the market opens. Following the announcement, a teleconference will be held at 9:00 a.m. Eastern Time, which can be accessed via phone or web. The company emphasizes its commitment to innovation and quality, with a particular focus on expanding the supply of transplantable organs through its subsidiary, Lung Biotechnology PBC. The release contains forward-looking statements that are subject to risks and uncertainties.